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BACKGROUND: The interval between the onset of Barrett’s oesophagus (BO) and oesophageal adenocarcinoma (OAC) can be termed
the incubation period. However, the unrecorded onset of BO precludes its direct observation.
METHODS: Determining the range of intervals between BO diagnosis and OAC within the longest observational BO follow-up study.
Exclusion criteria were presence of high-grade dysplasia (HGD) or OAC at baseline, death within o2 years of BO diagnosis,
oesophagectomy without HGD/OAC and loss to follow-up. A total of 133 patients (M/F 73/60) were taken into account.
RESULTS: In 1967 person years of follow-up there were 13 cases of HGD/OAC, (0.66% p.a.; 95% CI 0.58–0.74), 96 patients died
without HGD/OAC and 24 survived without HGD/OAC. The mean intervals between BO diagnosis and either HGD/OAC, death
or end of follow-up were 10.8, 12.6 and 25.5 years, respectively, and the mean ages at endpoint were 72.5, 80.0 and 68.3 years,
respectively. The survivors without HGD/OAC had a lower age at BO diagnosis (mean 42.8 vs 61.2 and 67.4 years, Po0.001).
Baseline presence of low-grade dysplasia was associated with progression to HGD/OAC (log rank Po0.001).
CONCLUSION: The Rotterdam BO follow-up cohort revealed a long incubation period between onset of BO and development of
HGD/OAC, in patients without HGD/OAC at baseline as illustrated by 24 patients diagnosed with BO at a young age and followed
for a mean period of 25.5 years. Their tumour-free survival established a minimum incubation period, suggesting a true incubation
period of three decades or more.
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Oesophageal cancer is currently the sixth leading cause of cancer-
related death worldwide. Since the 1980s the incidence of
oesophageal cancer has been rising by about 4–10% annually.
(Pace et al, 2007; Odze, 2008). In the United States, SEER data over
the period 1973–2004 demonstrated a rising oesophageal cancer
incidence of 45% in Caucasian males and 3.6% in Caucasian
females (Brown et al, 2008). These rises solely resulted from
dramatic increases in the incidence of oesophageal adenocarcinoma
(OAC) of 463% in males and 335% in females, as the squamous cell
carcinoma incidence by sex simultaneously fell by 50% and 29%
respectively (Brown et al, 2008). In The Netherlands, over
the 15-year period from 1989 to 2003, the OAC incidence rose
annually by 7.2% in males and 3.5% in females (van Blankenstein
et al, 2007b). There can be little doubt about the involvement of the
increasing incidence of Barrett’s oesophagus (BO) (van Soest et al,
2005; de Jonge et al, 2010). BO constitutes a premalignant
condition leading to OAC. It is characterised by a metaplastic
change of the oesophageal squamous mucosa into columnar-lined
epithelium, with or without specialised intestinal metaplasia, and
caused by chronic gastro-oesophageal reflux (GORD) (Pace et al,
2007; Sharma et al, 2009). Various cohort studies have reported
wide ranges in the incidence rates of OAC in BO patients (Shaheen
et al, 2000). After excluding both prevalent cancers and high-grade
dysplasia (HGD), a recent systematic review and meta-analysis
of OAC and HGD incidence rates in BO patients, arrived at an
incidence of OAC and HGD combined of 10.2/1000 person years
(Sikkema et al, 2010). The incidence of OAC alone was 6.3/1000
person years and the incidence of HGD alone was found to be
4.0/1000 person years (Sikkema et al, 2010).
The reported wide ranges of observed intervals between BO
diagnosis and incident OAC may either be due to large individual
differences in progression rates or to large differences in the stage
of diagnoses of BO. As practically no reliable long-term predictors
of malignant progression have been identified, there is usually no
indication at diagnosis which BO patients will survive to incident
OAC (Ong et al, 2010). On the other hand, studies of large groups
of BO patients referred by general practitioners have generated
some insights into the patterns of BO incidence, such as its age-
specific increase and the delayed BO onset of about 20 years in
females (van Blankenstein et al, 2005; van Soest et al, 2005;
Derakhshan and McColl, 2009).
There is by definition an interval between the onset of BO and
incident OAC, which we will term the incubation period. In 1992
Cameron and Lomboy estimated that BO developed at a mean age
of 40 years, whereas the mean age at OAC diagnosis was 64 years.
They concluded from this observation that the average incubation
period from BO to OAC was more than 20 years (Cameron and
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Lomboy, 1992). A mathematical model based on the observed OAC
incidence in a Danish cohort, required all OAC cases to have
acquired BO before the age of 45. This also suggested an incu-
bation period of several decades (Van Blankenstein et al, 2007a).
Unfortunately the unrecorded onset of BO precludes measuring its
duration by direct observation. Currently the only available
surrogate for the date of BO onset is the date of BO diagnosis.
It is therefore impossible to do more than estimate a minimal
incubation period. This might be achieved by examining the length
of the intervals between BO diagnosis and incident OAC in very
large BO follow-up cohorts and wait until all patients had either
developed OAC or died from unrelated causes. However, such
cohorts are as yet non-existent. In the current study we have now
employed the Rotterdam BO follow-up cohort as the best available
alternative. This cohort originally comprised of 166 patients with
long-segment BO and has now been followed-up for over 30 years.
We updated the outcomes of this cohort 14 years after the previous
complete assessment in 1994 (van der Burgh et al, 1996). Besides
seeking data aiding an estimate of the incubation period, our main
objectives were, first, to reassess the incidence rate of OAC in the
full cohort, and second to assess the predictive value of the length
of BO and the presence of low-grade dysplasia (LGD) at index
endoscopy for malignant progression.
PATIENTS AND METHODS
Study population
All 166 patients of the original Rotterdam BO cohort were
reassessed. This cohort consisted of a selection of patients with
BO from our records, meeting given criteria and in whom BO was
diagnosed between November 1973 and May 1986. The original
inclusion criteria were as follows: BO over at least 3 cm of the full
circumference and at least 3 months of follow-up after the first BO
diagnosis. Patients developing OAC within 3 months of their first
BO diagnosis were excluded (Van der Veen et al, 1989). Besides
obvious additional exclusion criteria, such as HGD at index
endoscopy and loss to follow-up, we now added one new exclusion
criterion, non-OAC-related death within 2 years of inclusion. This
criterion was based on the consideration that a large proportion of
patients had been diagnosed in a university hospital and therefore
were likely to have been admitted for more life-threatening
conditions than GORD, resulting in a reduced life expectancy,
which was in fact observed in the 1996 study (van der Burgh et al,
1996). Until 2001 this was a purely observational study and the
cohort did not undergo endoscopic surveillance. Patients were
only re-endoscoped for symptoms. However, after 2001 a large part
of the cohort was entered into an endoscopic surveillance
programmes.
Data collection
Clinical follow-up All available cohort data, including the histo-
logy revisions collected in 2001 were used as input (Hage et al,
2004). The general practitioners or specialists caring for the 42
patients surviving in 2001 were questioned by mail as to patient’s
vital status and the presence of signs or symptoms suggestive of
oesophageal cancer. Whenever necessary, additional information
was obtained by telephone, not only from clinicians, but also from
nursing homes, the patients themselves or their relatives. For
patients who had died, the date and cause of death were
ascertained. For patients who had developed oesophageal cancer,
detailed information on histology, treatment and outcome was
acquired through the clinicians involved.
Endoscopy and histology Data on the length of BO at index
endoscopy were obtained from the original endoscopy reports.
Over the years all biopsy samples from BO had been taken with
standard biopsy forceps, with additional biopsy samples taken
from any observed irregularities.
For a partial reassessment of the cohort, published in 2004 a
revision of all available histology of 155 patients had been reviewed
by a single expert pathologist (Hage et al, 2004). Where available
these histology results were used, in their absence we fell back on
the original histopathology results. After 2001 a large proportion of
the 42 survivors had undergone repeated surveillance endoscopies,
of which the date and the results were obtained from the gastro-
enterologist involved.
Data analysis
Three events were chosen as primary outcomes: death without
HGD/OAC (HGD/OAC), incident HGD/OAC and survival without
HGD/OAC. The periods between BO diagnosis and event (BPE)
were calculated by outcome group and sex.
Statistical analysis
The ages at BO diagnosis, length of BPE and age at event were
calculated for the three outcome groups and statistically compared
with the w2-test, Fisher’s exact test or the Student’s t-test where
appropriate. Analysis of the time schedule of incidence of HGD/
OAC was performed with the Kaplan–Meier survival analysis, testing
for statistical significance with the log-rank test and the Cox regression
model. All statistical analyses were performed with SPSS (Statistical
Package for the Social Sciences version 17, IBM, Somer, NY, USA).
Two-sided P-values below 0.05 were considered significant.
RESULTS
Baseline characteristics
Thirty-three patients of the original cohort of 166 BO patients
were excluded for the following reasons: presence of HGD at
baseline (n¼ 2), death within 2 years of BO diagnosis (n¼ 19),
oesophagectomy without HGD/OAC (n¼ 1, stricture misclassified
as cancer) and loss to follow-up (n¼ 11) (Figure 1). The remaining
133 BO patients were included for analysis (M/F 73/60), with an
average age at BO diagnosis of 62.4 years (range 14.4–92.3 years),
an average BO length of 6.5 cm (range 3–15 cm) and a mean BPE
of 14.7 years (range 2.1–32.0 years) (Table 1).
Differences between sexes
The males in the cohort were significantly younger at BO diagnosis
than females (57.4 years vs 68.3 years; Po0.001). They also had
significantly longer BO segments (7.2 cm vs 6.0 cm; P¼ 0.03) and
a longer BPE (16.0 years vs 13.3 years; P¼ 0.05).
Outcomes of HGD/OAC
Thirteen patients (M/F 10/3) developed HGD or OAC during
follow-up. These were all symptomatic cases of HGD/OAC as the
patients were not under endoscopic surveillance and were only
reinvestigated for symptoms. These cases were observed over a
period of 1967 patient years, 1 per 151 years of follow-up or 0.66
per annum (95% CI 0.58–0.74). Eight patients (M/F 6/2) under-
went oesophagectomy, with three postoperative deaths and a mean
survival of 8.9 years (range 4.4–15.5) in the survivors. Mean
survival in five unoperated patients was 1 year, with two patients
dying of OAC and three of co-morbidity. Eventually, in six cases
(4.5%) the cause of death was related to HGD/OAC (two directly
from OAC, one from metastatic disease 4.4 years after oesopha-
gectomy and three from surgical complications). Two patients
who developed HGD/OAC were alive in 2008, their intervals
between BO diagnosis and HGD/OAC diagnosis amounted 19.2
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and 20.4 years and their current survival post-oesophagectomy was
3.7 and 12.1 years, respectively (Table 2).
Subjects who died without developing HGD/OAC
Ninety-six patients (72%; M/F 44/52) died without HGD/OAC after
an average BPE of 12.6 years (range 2.1–26.8). Their mean age at
BO diagnosis was 67.4 years (range 29.6–92.3) and the mean age
at death was 80.0 years (range 35–100). The mean age at which
the males had been diagnosed with BO was 63.5 vs 70.7 years in
females (Po0.001), the male BPE was 12.7 vs 12.6 years in females
and the ages at event were 76.2 vs 83.2 years (Po0.0001),
respectively (Table 1).
Survivors without HGD/OAC
Twenty-four patients (18%; M/F 19/5, mean age 68.3 years, range
43.7–92.9) were alive on 1 February 2008 without HGD/OAC.
In this group there were no differences by sex in mean ages at BO
diagnosis, BPE or mean age at event. However, the differences in
all these three parameters with the two previous outcome groups
were very significant. (Figure 3) Survivors had an average age at
inclusion of 42.8 years vs 67.4 years in the deceased group; their
mean BPE was 25.5 years and the mean age at event was 68.3 years.
(Table 1 and Figure 3) The mean BO length was 6.0 cm (range
3–10 cm) in the survivors and 6.4 cm (range 3–15 cm) in the
deceased group. This difference in BO length was not responsible
for the difference in survival (log rank P¼ 0.8) (Table 3).
Factors predictive of HGD/OAC during follow-up
More males (78.6%) than females developed HGD or OAC.
The mean age at BO diagnosis was lower in males, 58.7 (range
37.2–77.8) vs 69.7 (range 57.2–76.4) years, but the mean male
BPE of 12.2 years (range 3.8–20.4) was far longer than the 6 years
in females (range 1.6–10.4) (both P-values NS) whereas the mean
ages at end point were similar 75.6 (range 58.8–86.5) vs 71.5 years
(range 56.4–88.7) (Table 1).
Table 1 Characteristics of total cohort; deceased subjects without HGD/OAC, subjects having developed HGD/OAC and survivors without HGD/OAC
Outcome category N Age at BO diagnosis mean (range) BPE mean (range) Age at end point mean (range)
Total cohort 133 62.4 (14.4–92.3) 14.7 (1.6–32.0) 77.2 (35.0–100.0)
Males 73 57.4 (14.4–84.3) 16.0 (2.3–32.0) 73.5 (35.0–98.4)
Females 60 68.3 (27.0–92.3) 13.3 (1.6–31) 81.6 (48.3–100.0)
Died without HGD/OAC 96 67.4 (29.6–92.3) 12.6 (2.1–26.8) 80.0 (35.0–100.0)
Males 44 63.5 (32.7–84.3) 12.7 (2.6–25.9) 76.2 (35.0–98.4)
Females 52 70.7 (29.6–92.3) 12.6 (2.1–26.8) 83.2 (48.3–100.0)
HGD/OAC 13 61.2 (37.2–77.8) 10.8 (1.6–20.4) 72.5 (56.4–88.7)
Males 10 58.7 (37.2–77.8) 12.2 (3.8–20.4) 71.5 (56.4–88.7)
Females 3 69.7 (57.2–76.4) 6.0 (1.6–10.4) 75.6 (58.8–86.5)
Survivors without HGD/OAC 24 42.8 (14.4–68.9) 25.5 (20.8–32.0) 68.3 (43.7–92.9)
Males 19 42.7 (14.4–68.9) 25.6 (22.2–32.0) 68.2 (43.7–92.9)
Females 5 43.1 (27.0–63.6) 25.5 (20.8–31.0) 68.6 (56.8–84.4)
Abbreviations: BO¼ Barrett’s oesophagus; BPE¼ period between Barrett’s diagnosis and endpoint; endpoint¼ development of HGD/OAC or death or end of follow-up
(February 2008); HGD¼ high-grade dysplasia; OAC¼ oesophageal adenocarcinoma.
Barrett’s diagnosis
1973–1986
166 patients 
Excluded 22 patients 
HGD/OAC
(n = 13)
- Eight oesophagectomy
 - One postoperative death
 - mean survival 7.7 year
- Five no treatment
 - mean survival 1 year
→ Five deaths caused by ACO
Death without
HGD/OAC
(n = 96)
Included 133 patients
Survivors
(n = 24)
Follow-up data:
155 patients 
Oesophagectomy
without HGD/OAC
(n = 1)
HGD/OAC <12
months BO diagnosis
(n = 2)
Death <2 years of BO diagnosis by
other causes than HGD/OAC
(n = 19)
mean age at diagnosis: 67.0 (s.d. 15.0)
- 47% Cardiovascular disease
- 26% Non-oesophageal malignancy
- 27% Unknown without signs of
oesophageal cancer
Figure 1 Cohort diagram describing the cohort details, the number of excluded patients, the number of included patients and their outcomes.
HGD¼ high-grade dysplasia; OAC¼ oesophageal adenocarcinoma.
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No significant differences were demonstrated in age at BO
diagnosis between patients developing HGD/OAC and patients
who died without developing HGD/OAC. The average BO length
was longer in the HGD/OAC group, 8.4 and 6.4 cm in the overall
cohort (P¼ 0.04) (Table 3).
Twenty-seven (20%) patients were diagnosed with LGD at
inclusion. In the absence of endoscopic surveillance until 2001, no
data were available about new cases of LGD developing before
2001, in practice no cases were observed after 2001. There were no
differences in age at BO diagnosis or follow-up interval between
patients with and without LGD at inclusion. However, the length of
the BO segment at diagnosis was significantly longer in the
patients with LGD, 8.3 vs 6.1 cm (P¼ 0.001) (Table 4).
The baseline presence of LGD was associated with progres-
sion to HGD/OAC (Log rank Po0.001) (Figure 2); 26% of
patients with baseline LGD developed HGD/OAC compared
with 5.6% in the group without baseline LGD (Table 4). A BO
length 48 cm was in univariate analysis also associated with the
progression to HGD/OAC (P¼ 0.04) (8.3 vs 6.3 cm); however,
using a Cox-regression model the only factor significantly asso-
ciated with progression was the presence of LGD at inclusion
(P¼ 0.004).
DISCUSSION
The Rotterdam BO cohort, ranging back to 1973, is to our
knowledge the longest running observational cohort of long-
segment BO patients. The follow-up results of this cohort were
previously published in 1989 and 1996 (Van der Veen et al, 1989;
van der Burgh et al, 1996). An analysis limited to the 105 patients
with confirmed IM at baseline was published in 2004 (Hage et al,
2004). On the basis of current BSG guidelines and United States
literature, we have now abandoned this entry criterion of confirmed
IM (Playford, 2006; Riddell and Odze, 2009). This is therefore the
third follow-up report of the full cohort. Since this study is a continua-
tion of the previous studies on the full cohort, we chose to adhere to
the original criterion and excluded prevalent HGD/OAC cases with
a diagnosis within 3 months of BO diagnosis. Even though adoption
of 1-year interval for prevalent cancers is nowadays more common.
This did, however, not affect our results given the fact that no patient
was diagnosed with OAC within 1 year after diagnosis of BO.
In our search for the incubation period from BO to HGD/OAC
we in particular focused on patients who were diagnosed with BO
at a young age. This study revealed the important finding that
there is a long incubation period between onset of BO and
Table 2 Outcomes in patients with HGD/OAC
Patient Treatment Interval BO diagnosis to HGD/OAC (years) Survival after HGD/OAC diagnosis (years) Cause of death
1 Oesophagectomy 10.4 0.3 OAC
2 Oesophagectomy 4.8 0.2 OAC
3 Oesophagectomy 6.6 15.5 Myocardial infarction
4 No treatment 2.3 3.9 Myocardial infarction
5 Oesophagectomy 14.3 0 OAC
6 Radiation therapy 15.9 0.2 OAC
7 Oesophagectomy 20.4 3.7 Not applicable; alive
8 Oesophagectomy 1.6 4.4 OAC
9 No treatment 10.9 9.3 Heart failure
10 Oesophagectomy 19.2 7.9 Not applicable; alive
11 No treatment 5.9 0.1 Myocardial infarction
12 Oesophagectomy 13.3 13 No oesophageal carcinoma
13 No treatment 15.4 2.4 No oesophageal carcinoma
Abbreviations: BO¼ Barrett’s oesophagus; HGD/OAC¼ high-grade dysplasia/oesophageal adenocarcinoma; survival¼ period between diagnosis of HGD/OAC and death or
February 2008.
Table 3 Length of BO in different subject groups
Groups Length BO mean (range) (cm)
Total Cohort 6.0 (3–15)
Died without HGD/OAC 6.4 (3–15)
HGD/OAC 8.3 (3–14)
Survivors without HGD/OAC 6.0 (3–10)
Abbreviations: BO¼ Barrett’s oesophagus; HGD/OAC¼ high-grade dysplasia or
oesophageal adenocarcinoma.
Table 4 Differences between subjects with LGD at baseline and patients
without LGD
No LGD (s.d.) LGD (s.d.) P-value
Mean age at BO diagnosis 61.59 years (15.97) 65.36 years (12.54) 0.26
Length BO at diagnosis 6.08 cm (2.89) 8.26 cm (3.45) 0.001
BPE 15.03 years (8.26) 13.84 years (7.07) 0.49
Abbreviations: BO¼ Barrett’s oesophagus; BPE¼ period between Barrett’s diagnosis
and endpoint; endpoint¼ development of high-grade dysplasia/oesophageal adeno-
carcinoma or death or end of follow-up (February 2008); LGD¼ low-grade dysplasia.
0.5
0.4
0.3
0.2
0.1
0.0
0.0 10.0 20.0 30.0 40.0
BO subjects without dysplasia
BO subjects with LGD
Log rank P< 0.001
Follow-up BO subjects
Pr
op
or
tio
n 
of
 p
ro
gr
e
ss
io
n 
to
 s
H
G
D/
AC
O
Figure 2 Kaplan–Meier curve demonstrating a difference in progression
to HGD/OAC in subjects with BO with or without LGD. BO¼ Barrett’s
oesophagus; HGD¼ high-grade dysplasia; LGD¼ low-grade dysplasia;
OAC¼ oesophageal adenocarcinoma.
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development of HGD/OAC, as we have demonstrated in Figure 3.
In fact in the 24 survivors without HGD/OAC the mean follow-up
was 25.5 years, exceeding 30 years in three individuals.
In view of the real date of the onset of BO being unknown, this
incubation period is very likely to be in excess of the three decades
now observed. The further follow-up of our survivor group
will probably extend this observed incubation period even further.
The concept of an incubation period is also compatible with
the findings in the outcome group of subjects who died with-
out HGD/OAC. The incidence of BO is age related, probably
reaching its maximum after age 50 in males and 70 in females
(van Blankenstein et al, 2005). Although the presence of some
cases of asymptomatic HGD/OAC in this outcome group cannot
be excluded, the onset of BO apparently occurred too late to bridge
the incubation period to incident HGD/OAC. This hypothesis
would imply that not only the survivors, but also the HGD/OAC
outcome group, should have contracted BO at a relatively early
age. This is illustrated in Figure 3, the length of the incubation
period was inversely related to the age at BO diagnosis. This
supports our hypothesis that the average incubation period is long
and that shorter incubation periods in elderly patients are not
related to a faster progression, but to a delayed diagnosis of BO.
The reason, why, with a few exceptions, the length of the interval to
the event in the former group fell far short of our hypothetical
several decades, is likely to have been that, at the time when these
patients were around 30–40 years of age, upper GI endoscopy, let
alone BO diagnosis, was still uncommon. In this respect our
survivors were more fortunate in being diagnosed at an earlier age.
The recently reported steadily declining age at BO diagnosis,
observed between 1990 and 2005, would support this hypothesis
(Wall et al, 2009). A case report published in 1984 contrasts our
hypothesis and describes a short incubation period from Barrett’s
metaplasia to cancer, however, this case report lacked important
information to substantiate this claim (Dahms and Rothstein,
1984).
In our cohort we demonstrated that LGD at inclusion is a clear
risk factor for progression to HGD and eventually adenocarcinoma.
However the issues of inter and intraobserver variability of
dysplasia in Barrett’s epithelium have been reported by several
studies (Cameron, 1997; Montgomery et al, 2001; Conio et al, 2003;
Dulai et al, 2005; Kerkhof et al, 2007). Recent large studies
including a nationwide Dutch study concluded that, even when
taking this variability into account, LGD remains a significant risk
factor for progression and can be used as a marker for the need of
more intense surveillance (Skacel et al, 2000; de Jonge et al, 2010).
Another possible risk factor in our cohort was the presence of a
BO segment longer than 8 cm at diagnosis, this is, however, a more
controversial factor. Although some studies were in line with
our observation (Van der Veen et al, 1989; Iftikhar et al, 1992;
Menke-Pluymers et al, 1993), others could not demonstrate an
association between BO length and progression to HGD (Rudolph
et al, 2000; Gatenby et al, 2007). It might be argued that the
significantly greater length of BO and far higher prevalence of LGD
in the HGD/OAC group as compared with the survivors and death
without HGD/OAC outcome groups could signify a more severe
form of BO with a shorter incubation period. The presence of LGD
at index endoscopy has been found to indicate a more advanced
stage in malignant progression (de Jonge et al, 2010). We believe
that, in view of the great uncertainty about the true date of onset of
BO, the higher prevalence of LGD at baseline in the HGD/OAC
group was a sign of more advanced malignant progression than in
the other two outcome groups.
The question rises whether the current findings were consistent
with the two previous updates published in 1989 and 1996 and, in
addition, whether they were compatible with other BO follow-up
studies. The incidence rate of HGD/OAC combined was 0.66/100
patient years (95% CI 0.58–0.74), not dissimilar from the 0.59/100
patient years and 0.56/100 patient years OAC incidence observed
in the two previous studies, in which all cases later reclassified as
HGD were scored as OAC (Van der Veen et al, 1989; van der Burgh
et al, 1996). The results were also compatible with a recent meta-
analysis of the OAC risk in BO patients, which arrived at a pooled
estimate for the incidence of OAC of 0.62/100 person years
(Sikkema et al, 2010). Our study was, until 2001, an observational
study, so all endoscopies diagnostic for HGD/OAC were performed
for symptoms. These symptoms ranged from dysphagia, increasing
heartburn or other reflux symptoms. The fact that HGD can cause
dysphagia is not always recognised (Gatenby et al, 2009). It is
interesting to note that the only patient diagnosed with OAC after
2001 became symptomatic during the interval between two
surveillance endoscopies.
Should our hypothesis about the protracted latent period
between BO onset and OAC incidence be correct, then patients
at highest risk of developing OAC would be those with a BO onset
at a relatively early age. For efficient endoscopic surveillance they
should be identified shortly after BO onset, which would require
population screening for BO in the male 40-year age group. This
would, however, appear to be a counsel of perfection, although
an acceptable non-endoscopic technique was recently proposed
(Lao-Sirieix et al, 2009). In practice general practitioners could
be encouraged to refer male patients with reflux symptoms for
endoscopy before prescribing PPI’s. This would not only save
money now spent on unnecessary PPI consumption but might also
improve, if only to a limited extent, the ascertainment of BO at an
earlier age (Van Soest et al, 2006, 2008).
In conclusion, this third update of the Rotterdam long BO
segment observational cohort, (i.e., follow-up without endoscopic
surveillance), now spanning over 30 years, produced HGD/OAC
incidences consistent with the two previous surveys. However, the
most relevant finding was the length of the interval between BO
diagnosis and the end of follow-up in the survivors without the
occurrence of HGD/OAC. In these survivors, in whom BO was
diagnosed at a 20 year earlier mean age than in the rest of the
cohort, this interval amounted to a mean of 25.5 years, with three
individuals exceeding 30 years. We interpret this observation as
indicating an incubation period between the onset of BO and
incident OAC of three or more decades. The combination of the
age-specific incidence of BO and such a protracted incubation
period may well explain why the great majority of BO patients do
not contract OAC.
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Figure 3 Age at event and age at diagnosis of BO patients developing
HGD/OAC and BO patients alive without HGD/OAC. BO¼ Barrett’s
oesophagus; LGD¼ low-grade dysplasia; HGD¼ high-grade dysplasia;
OAC¼ oesophageal adenocarcinoma. (Event is defined as development
of HGD/OAC in the HGD/OAC group and end of follow-up (February
2008) in the survivors).
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